PROG News and Press, Progenity Inc. From 05/08/23

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial mar...

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharma...

SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis , an event hosted by the Cro...

Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform No adverse events indicated in 14-day tox study for targeted therapeutics program ...

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth quarter and full year ended December 31, 2022 financial results on Thursday, March 30, 2023 after th...

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB2 program, reporting an average bioavailability of 37% for semaglutide,...

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB1 program, reporting an average bioavailability greater than 50% for a...

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-611 study titled “Potential effects of food on a novel Drug Delivery System (DDS) to deliver...

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced feedback from the United States Food and Drug Administration (FDA) on its clinical development plans for its PGN-600 program, an...

NEW YORK, NY / ACCESSWIRE / October 24, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PROG Holdings, Inc. ("PROG" or the "Company") (NYSE:PRG). If you suffered losses exceeding $50,000 investing in PROG stock or options ...